Alnylam Pharmaceuticals, Inc. (0HD2.L)
USD 243.84
(-0.72%)
USD 243.84
(-0.72%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -228.12 Million USD | 69.2% |
| 2022 | -740.6 Million USD | -12.03% |
| 2021 | -661.08 Million USD | 16.7% |
| 2020 | -793.66 Million USD | 13.94% |
| 2019 | -922.25 Million USD | -14.11% |
| 2018 | -799.42 Million USD | -66.06% |
| 2017 | -488.19 Million USD | -18.87% |
| 2016 | -409.45 Million USD | -47.84% |
| 2015 | -276.95 Million USD | -60.75% |
| 2014 | -388.67 Million USD | -108.3% |
| 2013 | -82.71 Million USD | -59.94% |
| 2012 | -107.55 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -60.3 Million USD | -262.57% |
| 2024 Q1 | -29.91 Million USD | 70.93% |
| 2024 Q2 | 63.61 Million USD | 223.99% |
| 2023 Q3 | 227.19 Million USD | 204.87% |
| 2023 Q4 | -102.92 Million USD | -145.3% |
| 2023 FY | - USD | 69.2% |
| 2023 Q1 | -135.74 Million USD | 22.12% |
| 2023 Q2 | -216.65 Million USD | -59.61% |
| 2022 Q3 | -247.44 Million USD | -36.26% |
| 2022 Q2 | -181.58 Million USD | -32.28% |
| 2022 FY | - USD | -12.03% |
| 2022 Q1 | -137.27 Million USD | 25.06% |
| 2022 Q4 | -174.3 Million USD | 29.56% |
| 2021 Q2 | -134.35 Million USD | 22.63% |
| 2021 Q4 | -183.18 Million USD | -7.83% |
| 2021 FY | - USD | 16.7% |
| 2021 Q1 | -173.65 Million USD | 5.54% |
| 2021 Q3 | -169.89 Million USD | -26.45% |
| 2020 Q4 | -183.83 Million USD | 15.14% |
| 2020 FY | - USD | 13.94% |
| 2020 Q3 | -216.62 Million USD | -13.62% |
| 2020 Q2 | -190.65 Million USD | 5.87% |
| 2020 Q1 | -202.54 Million USD | 30.78% |
| 2019 Q1 | -184.95 Million USD | 12.32% |
| 2019 FY | - USD | -14.11% |
| 2019 Q4 | -292.63 Million USD | -37.86% |
| 2019 Q3 | -212.26 Million USD | 8.67% |
| 2019 Q2 | -232.41 Million USD | -25.66% |
| 2018 Q2 | -190.11 Million USD | -31.82% |
| 2018 Q1 | -144.22 Million USD | -0.44% |
| 2018 FY | - USD | -66.06% |
| 2018 Q4 | -210.93 Million USD | 17.01% |
| 2018 Q3 | -254.15 Million USD | -33.68% |
| 2017 Q4 | -143.58 Million USD | -17.49% |
| 2017 FY | - USD | -18.87% |
| 2017 Q3 | -122.21 Million USD | -4.09% |
| 2017 Q2 | -117.4 Million USD | -13.43% |
| 2017 Q1 | -103.51 Million USD | 7.92% |
| 2016 Q1 | -105.42 Million USD | -20.57% |
| 2016 Q2 | -88.43 Million USD | 16.11% |
| 2016 Q4 | -112.41 Million USD | -8.95% |
| 2016 Q3 | -103.17 Million USD | -16.66% |
| 2016 FY | - USD | -47.84% |
| 2015 Q1 | -48.53 Million USD | -14.54% |
| 2015 FY | - USD | -60.75% |
| 2015 Q4 | -87.44 Million USD | -19.69% |
| 2015 Q3 | -73.06 Million USD | -7.56% |
| 2015 Q2 | -67.92 Million USD | -39.96% |
| 2014 Q4 | -42.37 Million USD | -0.69% |
| 2014 Q3 | -42.08 Million USD | 8.57% |
| 2014 Q2 | -46.02 Million USD | -10.09% |
| 2014 Q1 | -41.8 Million USD | -55.05% |
| 2014 FY | - USD | -108.3% |
| 2013 FY | - USD | -59.94% |
| 2013 Q4 | -26.96 Million USD | 8.5% |
| 2013 Q1 | -7.67 Million USD | 64.03% |
| 2013 Q2 | -18.6 Million USD | -142.3% |
| 2013 Q3 | -29.47 Million USD | -58.43% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | -21.34 Million USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Editas Medicine, Inc. | -163.11 Million USD | -39.851% |
| Dynavax Technologies Corporation | 9.66 Million USD | 2460.035% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 332.156% |
| Perrigo Company plc | 646.2 Million USD | 135.302% |
| Illumina, Inc. | -608 Million USD | 62.48% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 102.112% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 49.195% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 97.977% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 107.006% |
| Heron Therapeutics, Inc. | -103.79 Million USD | -119.787% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 104.901% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -511.863% |
| Waters Corporation | 1.02 Billion USD | 122.316% |
| Biogen Inc. | 2.37 Billion USD | 109.597% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -160.927% |
| Evolus, Inc. | -41.81 Million USD | -445.613% |
| Adicet Bio, Inc. | -136.53 Million USD | -67.079% |
| Cara Therapeutics, Inc. | -117.65 Million USD | -93.898% |
| bluebird bio, Inc. | -167.16 Million USD | -36.468% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | -51.971% |
| FibroGen, Inc. | -261.4 Million USD | 12.733% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 113.603% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -413.362% |
| Homology Medicines, Inc. | -47.75 Million USD | -377.68% |
| Geron Corporation | -174.78 Million USD | -30.517% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | -147.745% |
| Myriad Genetics, Inc. | -67.8 Million USD | -236.462% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -126.25% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 54.945% |
| Zoetis Inc. | 3.68 Billion USD | 106.191% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -351.082% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 119.597% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 173.52% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 104.954% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -532.229% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 0.821% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 14.239% |
| Verastem, Inc. | -83.16 Million USD | -174.296% |
| Nektar Therapeutics | -243.1 Million USD | 6.164% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | -1.391% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | -159.273% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 48.059% |
| OPKO Health, Inc. | -65.51 Million USD | -248.191% |
| Exelixis, Inc. | 196.6 Million USD | 216.032% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 154.824% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 310.591% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -309.142% |
| uniQure N.V. | -253.1 Million USD | 9.869% |
| Imunon, Inc. | -20.78 Million USD | -997.671% |
| Blueprint Medicines Corporation | -474.61 Million USD | 51.935% |
| Insmed Incorporated | -654.73 Million USD | 65.158% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 150.475% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 33.967% |
| TG Therapeutics, Inc. | 26.1 Million USD | 974.027% |
| Incyte Corporation | 919.42 Million USD | 124.811% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 54.854% |